



## Dr. Leena Gandhi

Dr. Leena Gandhi currently serves as Vice President, Immuno-Oncology Development at Eli Lilly. She previously was an associate professor of medicine at NYU Perlmutter Cancer Center where she served as Director of Thoracic Medical Oncology from 2016-2018. She completed a Ph.D. in Molecular and Cell Biology at UC Berkeley in 1998 prior to attending medical school at NYU. After completion of her MD degree, she completed residency training in internal medicine at MGH and a hematology-oncology fellowship at Dana-Farber Cancer Institute. She worked as a thoracic oncologist at DFCI from 2008-2016 and served as the Director of Thoracic Clinical trials from 2013-2016. While at DFCI she also worked in the Early Drug Development Center as the thoracic phase I oncologist. Her focus of research has been on novel therapeutics in lung cancer with a focus on immuno-oncology and biomarkers of immunotherapy response in lung cancer as well as modulation of the immune microenvironment by chemotherapies and other therapies. She was a lead investigator on clinical trials leading to FDA approval of alectinib, nivolumab, and pembrolizumab regimens in lung cancer and helped in defining PD-L1 biomarkers used for pembrolizumab therapy in NSCLC.